Biography and Research Information
OverviewAI-generated summary
Karthikeyan Mythreye's research investigates the molecular mechanisms underlying cancer progression, with a particular focus on ovarian cancer. His work explores the roles of specific signaling pathways, such as TGF-beta, and their interactions with cellular components like SOX2 and HuR. Mythreye examines how these pathways influence cancer cell behavior, including anoikis resistance, metastasis, and adaptation to challenging microenvironments like the ascites found in ovarian cancer patients.
His publications detail the involvement of factors such as PVT1, a stress-responsive lncRNA, in driving metastasis and chemoresistance in ovarian cancer. Mythreye also studies the impact of hypoxia-induced inhibin on tumor growth and vascular permeability. Furthermore, his research extends to bioinformatic analyses of signaling networks, such as the inhibin-betaglycan-endoglin network, to identify prognostic markers in various solid tumors.
Mythreye's scholarship metrics include an h-index of 29, with over 3,000 citations across more than 200 publications. He is actively involved in recent research, with publications in 2021, 2022, and a literature review in 2024.
Metrics
- h-index: 29
- Publications: 223
- Citations: 3,043
Selected Publications
-
Targeting Mediator Kinase Cyclin-Dependent Kinases 8/19 Potentiates Chemotherapeutic Responses, Reverses Tumor Growth, and Prolongs Survival from Ovarian Clear Cell Carcinoma (2025)
-
Loss of the predicted cell adhesion molecule MPZL3 promotes EMT and chemoresistance in ovarian cancer (2024)
-
Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer (2024)
-
Drp1 splice variants regulate ovarian cancer mitochondrial dynamics and tumor progression (2024)
-
Targeted therapy in high grade serous ovarian Cancer: A literature review (2024)
-
Extracellular signals induce dynamic ER remodeling through αTAT1-dependent microtubule acetylation (2024)
-
Phosphoproteomic profiling identifies DNMT1 as a key substrate of beta IV spectrin-dependent ERK/MAPK signaling in suppressing angiogenesis (2024)
-
RETRACTED: Advancing electric demand forecasting through the temporal fusion transformer model (2024)
-
Abstract B058: Targeting mediator kinase CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma (2024)
-
Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer (2024)
-
GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15 (2024)
-
GPX3 supports ovarian cancer tumor progression <i>in vivo</i> and promotes expression of GDF15 (2024)
-
Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 Mediator kinase inhibition (2023)
-
Alternative splice variants of the mitochondrial fission protein <i>DNM1L</i> /Drp1 regulate mitochondrial dynamics and tumor progression in ovarian cancer (2023)
-
Beta <scp>IV</scp> spectrin inhibits the metastatic growth of melanoma by suppressing <scp>VEGFR2</scp>‐driven tumor angiogenesis (2023)
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics